drugset / Trial / NCT06435351
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
NaSingle-groupOpen-labelTreatment
Summary
This is a pilot protocol to evaluate the safety, feasibility, and immunogenicity of a personalized breast cancer vaccine based utilizing whole exome sequencing data of a patient's residual breast tumor following neoadjuvant chemotherapy.
Timeline
- Start
- 2024-06-12
- Primary completion
- 2029-05
- Completion
- 2029-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dendritic Cell (DC) Vaccine | Vaccine | 40 cells | Other |
| Subject | Dendritic Cell (DC) Vaccine | Vaccine | 50 cells | Other |